AR050251A1 - Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto - Google Patents
Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuestoInfo
- Publication number
- AR050251A1 AR050251A1 ARP050102198A ARP050102198A AR050251A1 AR 050251 A1 AR050251 A1 AR 050251A1 AR P050102198 A ARP050102198 A AR P050102198A AR P050102198 A ARP050102198 A AR P050102198A AR 050251 A1 AR050251 A1 AR 050251A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carbonyl
- amino
- heterocyclyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Estos compuestos pueden utilizarse para preparar medicamentos, en particular como inhibidores de sintasa de aldosterona. Pueden ser empleados para la prevencion a retardo del avance del estado de hipocalcemia, hipertension, insuficiencia cardíaca congestiva, insuficiencia renal aguda, restinitis y ateroesclerosis, entre otras. Reivindicacion1: Compuestos de la formula general 1 en la cual X es C; Y es C, si Z es C, es también N; Z es C o un enlace; R es hidrogeno, alquilo C1-8, alcoxi C1- 8-alquiloC0-4, halogeno o trifluormetilo; R1 es heterociclilo no saturado-alquilo C0-4, radical que está sin substituir o substituido con 1-4 alquilo C1-8-sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquilo C0-8-carbonil-alquil C1-8-amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8, alcoxi C1-8-carbonilo, heterociclilo o arilo, en donde heterociclilo o arilo están sin substituir o substituidos con 1-4 alquilo C1_8, alquil C1-8-sulfonilo, halogeno, cioano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8.carbonil-amino, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8-amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, caboxi-alquilo C0-4, alcoxilo C1-8-carbonilo; R2 a) es hidrogeno; o b) es alquilo C1-8, cicloalquilo C3-8, halogeno, carboxi-alquilo C1-4, alcoxi C1-4-carbonil-alquilo C1-4, alquil C0-4-carbonilo, aril-alquilo C0-4 o heterociclilo no saturado-alquilo C0-4, radicales que están sin substituir o substituidos con 1-4 alquilo C1-8, alquil C0-8-carbonilo, alquil C1-8 -sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8-amino, cabamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8, alcoxi C1-8-carbonilo, heterociclilo, arilo, en donde heterociclilo o arilo están sin substituir o substituidos con 1-4 alquilo C1-8, alquil C0-8-carbonilo, alquilo C1-8-sulfonilo, halogeno, ciano, oxo, trialquil C1-4-sililo, trifluormetoxilo, trifluormetilo, alquil C0-8-carbonil-amino, alquil C0-8-carbonil-alquil C1-8- amino, carbamoílo, mono- o di-alquil C1-8-aminocarbonilo, carboxi-alquilo C0-4, alcoxilo C1-8 o alcoxi C1-8-carbonilo; n es un numero 0, 1 o 2; y las sales de los mismos, preferentemente las sales faramcéuticamente utiles de los mismos, y su sal, pro droga o compuesto en el cual uno o másátomos están reemplazados por sus isotopos no radioactivos estables, en particular, sal farmacéuticamente util; en los caules si Z es un enlace y R2 es hidrogeno, R1 no es carbazol, benzoimidoazolilo, benzotriazolilo, priridilo, pirimidinilo, pirazinilo o piridazinilo, o si Z es un enlace, R2 es hidrogeno y R1 es un radical heterocíclico que contiene S no saturado, monocíclico, estando estos radicales substituidos con alquil C0-8-carbonilo, ciano, arilo o heterociclilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH9162004 | 2004-05-28 | ||
CH11572004 | 2004-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050251A1 true AR050251A1 (es) | 2006-10-11 |
Family
ID=34993240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102198A AR050251A1 (es) | 2004-05-28 | 2005-05-27 | Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080076794A1 (es) |
EP (1) | EP1748986B1 (es) |
JP (1) | JP2008500999A (es) |
AR (1) | AR050251A1 (es) |
AT (1) | ATE490241T1 (es) |
BR (1) | BRPI0510412A (es) |
CA (1) | CA2568164A1 (es) |
DE (1) | DE602005025110D1 (es) |
IL (1) | IL179409A0 (es) |
TW (1) | TW200608978A (es) |
WO (1) | WO2005118541A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8680079B2 (en) * | 2004-05-28 | 2014-03-25 | Novartis Ag | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors |
TW200716105A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
EP2594557B1 (en) | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
CN105073762B (zh) | 2013-02-14 | 2017-03-08 | 诺华股份有限公司 | 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物 |
EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
UY35671A (es) | 2013-07-25 | 2015-02-27 | Novartis Ag | Bioconjugados de polipéptidos de apelina sintética |
SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
EP3887363A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽 |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859691A (en) * | 1987-07-08 | 1989-08-22 | Ciba-Geigy Corporation | Certain 1,2-benzisoxazole derivatives |
GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
DK0401707T3 (da) * | 1989-06-05 | 1994-10-17 | Daiichi Seiyaku Co | Heterocyclisk forbindelse, et farmaceutisk lægemiddel og fremgangsmåde til fremstilling af disse |
JP3170273B2 (ja) * | 1989-06-05 | 2001-05-28 | 第一製薬株式会社 | 縮合トリアジン誘導体及びその中間体 |
CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
DE69330557T2 (de) * | 1992-01-27 | 2002-06-20 | Janssen Pharmaceutica Nv | Pyrroloimidazolyl und imidazopyridinyl substituierte 1h-benzimidazolderivate als aromatase inhibitoren |
JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
JP2004536082A (ja) * | 1999-10-22 | 2004-12-02 | グラクソ グループ リミテッド | invivoイメージング |
US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
-
2005
- 2005-05-27 TW TW094117479A patent/TW200608978A/zh unknown
- 2005-05-27 CA CA002568164A patent/CA2568164A1/en not_active Abandoned
- 2005-05-27 US US11/597,615 patent/US20080076794A1/en not_active Abandoned
- 2005-05-27 WO PCT/EP2005/052418 patent/WO2005118541A2/en not_active Application Discontinuation
- 2005-05-27 DE DE602005025110T patent/DE602005025110D1/de not_active Expired - Fee Related
- 2005-05-27 AT AT05749325T patent/ATE490241T1/de not_active IP Right Cessation
- 2005-05-27 AR ARP050102198A patent/AR050251A1/es unknown
- 2005-05-27 BR BRPI0510412-2A patent/BRPI0510412A/pt not_active IP Right Cessation
- 2005-05-27 EP EP05749325A patent/EP1748986B1/en not_active Not-in-force
- 2005-05-27 JP JP2007513941A patent/JP2008500999A/ja active Pending
-
2006
- 2006-11-20 IL IL179409A patent/IL179409A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE490241T1 (de) | 2010-12-15 |
CA2568164A1 (en) | 2005-12-15 |
EP1748986B1 (en) | 2010-12-01 |
WO2005118541A2 (en) | 2005-12-15 |
TW200608978A (en) | 2006-03-16 |
IL179409A0 (en) | 2007-05-15 |
EP1748986A2 (en) | 2007-02-07 |
DE602005025110D1 (de) | 2011-01-13 |
US20080076794A1 (en) | 2008-03-27 |
BRPI0510412A (pt) | 2007-10-23 |
WO2005118541A3 (en) | 2006-02-02 |
JP2008500999A (ja) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050251A1 (es) | Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto | |
AR047706A1 (es) | Inhibidores de polimerasa viral | |
AR065901A1 (es) | Derivados de pirrolipirimidina | |
AR065280A1 (es) | Agentes antiparasitarios | |
AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
AR040076A1 (es) | Derivados de piridazin-3(2h)-ona | |
AR058006A1 (es) | Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos | |
ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
AR061737A1 (es) | Compuestos derivados de pirimidina, un peoceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20190337A1 (es) | NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
AR053778A1 (es) | Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa | |
AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
AR035783A1 (es) | Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3 | |
AR100817A1 (es) | Pirazoles y tetrazoles sustituidos con halógeno | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
AR066691A1 (es) | Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. | |
AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
AR071609A1 (es) | Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1 | |
AR045752A1 (es) | Derivados de quinazolina que poseen actividad antitumoral | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |